title: Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
abstract: We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response).
authors.affiliation: Department of Hematology, Service des Maladies du sang, INSERM U892, PRES LUNAM, University Hospital, Angers, France.
authors.forename: Aline
authors.initials: A
authors.lastname: Tanguy-Schmidt
authors.forename: Philippe
authors.initials: P
authors.lastname: Rousselot
authors.forename: Yves
authors.initials: Y
authors.lastname: Chalandon
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Cayuela
authors.forename: Sandrine
authors.initials: S
authors.lastname: Hayette
authors.forename: Marie-Christiane
authors.initials: MC
authors.lastname: Vekemans
authors.forename: Martine
authors.initials: M
authors.lastname: Escoffre
authors.forename: Françoise
authors.initials: F
authors.lastname: Huguet
authors.forename: Delphine
authors.initials: D
authors.lastname: Réa
authors.forename: André
authors.initials: A
authors.lastname: Delannoy
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Cahn
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Vernant
authors.forename: Norbert
authors.initials: N
authors.lastname: Ifrah
authors.forename: Hervé
authors.initials: H
authors.lastname: Dombret
authors.forename: Xavier
authors.initials: X
authors.lastname: Thomas
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001549:Benzamides / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality* / Q000628:therapy*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D015996:Survival Rate; D013997:Time Factors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D061349:Unrelated Donors
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate